Kairos Pharma holds annual shareholder meeting, approves reverse stock split authorization

Kairos Pharma, Ltd.

KAPA

0.00

Kairos Pharma held its 2026 annual shareholder meeting on June 29, 2026.
Shareholders ratified Weinberg & Company, P.A. as independent registered public accounting firm for the fiscal year ending Dec. 31, 2026.
Investors authorized a charter amendment allowing a reverse stock split between 1-for-3 and 1-for-250; the board will set any final ratio and timing.
Shareholders adopted amendments to the 2023 Equity Incentive Plan, adding 5 million shares and an automatic 5% annual increase for 10 years.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-031328), on June 30, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.